Triclosan

What It Is

Triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol) is a synthetic halogenated diphenyl ether with broad-spectrum antibacterial and antifungal activity. Molecular weight 289.5 g/mol, formula C₁₂H₇Cl₃O₂. It is a white crystalline powder, poorly soluble in water but readily soluble in ethanol and alkaline solutions.

First synthesised in the late 1960s by Swiss company Ciba-Geigy, triclosan entered surgical scrubs in the 1970s before appearing in over 2,000 consumer products by the 1990s — toothpastes, mouthwashes, antibacterial soaps, deodorants, and even plastic cutting boards.

In dentistry, the best-known formulation was triclosan + PVM/MA copolymer (polyvinyl methyl ether maleic acid), used in Colgate Total for decades as the benchmark anti-gingivitis dentifrice.

---

How It Works

Triclosan targets a single bacterial enzyme: ENR (enoyl-acyl carrier protein reductase), encoded by the fabI gene. This enzyme catalyses the final step in bacterial fatty acid elongation. Triclosan binds to the active site of ENR, forming a stable ternary complex (enzyme–NAD⁺–triclosan) that blocks fatty acid synthesis entirely.

Without fatty acids, bacteria cannot build or repair their cell membrane:

• At low concentrations — bacteriostatic (growth arrest)
• At higher concentrations — bactericidal (cell death)

The key limitation: fabI is a single target. Point mutations in this gene confer resistance. Prolonged sub-inhibitory exposure to triclosan selects for resistant strains of E. coli, S. aureus, and oral streptococci.

Triclosan also has low substantivity in the oral cavity — it does not adhere well to mucosal surfaces. This is why the PVM/MA copolymer is essential: it forms a film on teeth and gums from which triclosan slowly releases over several hours, extending its activity.

---

Efficacy

Clinical evidence

The evidence base, predominantly from industry-sponsored RCTs, is substantial.

Plaque and gingivitis. Gunsolley's 2006 meta-analysis of 16 six-month RCTs found that triclosan/copolymer dentifrice significantly reduced plaque scores and gingival bleeding compared with plain fluoride toothpaste — effect size moderate, but consistent. (PMID: 16208383)

Biofilm-gingival interaction. Haraszthy et al. (2010) showed that triclosan/copolymer paste attenuates the causal link between supragingival plaque levels and gingival bleeding, suggesting a chemical anti-inflammatory component beyond mechanical plaque removal. (PMID: 16965523)

Systematic review by Teles & Teles (2009) confirmed that triclosan/PVM-MA outperforms fluoride-only dentifrices as an antiplaque and antigingivitis agent — but emphasises the copolymer is non-negotiable for efficacy. (PMID: 15560802)

Limitations

• Most trials ran for only 6 months; long-term data are absent.
• Comparators were plain fluoride pastes, not modern antibacterial alternatives (cetylpyridinium chloride, zinc citrate).
• After Colgate removed triclosan from Total in 2019, no new large comparative trials have been published.

---

Safety

Endocrine disruption

Triclosan is lipophilic and crosses skin and mucous membranes readily. It accumulates in plasma, urine, breast milk, and adipose tissue with chronic use.

Thyroid axis. Aho et al. (2022) systematically reviewed 14 human epidemiological studies. Results are heterogeneous: several show inverse correlations between urinary triclosan and T3/T4/TSH concentrations; others show no association. The authors conclude data "suggest possible disruption of thyroid homeostasis" requiring further confirmation. (PMC9202756)

Reproductive hormones. Koeppe et al. (2022) reviewed evidence for triclosan's interaction with androgen receptors and estrogen-dependent pathways. Population data link urinary triclosan to altered male hormonal profiles. (PMID: 36232730)

Regulatory timeline

| Year | Regulator | Action | |------|-----------|--------| | 2016 | EU (EC 1223/2009) | Banned in cosmetics; limited exceptions for toothpaste ≤0.3% | | 2016 | FDA (USA) | Banned in antibacterial hand soaps — no demonstrated benefit over plain soap | | 2019 | Colgate | Voluntarily removed triclosan from Total globally | | 2020 | SCCS (EU) | Re-evaluated: safe in toothpaste ≤0.3% at limited exposure, but endocrine concern remains |

Cross-resistance risk

fabI mutations selected by triclosan confer cross-resistance to isoniazid (a tuberculosis antibiotic) and in some cases to fluoroquinolones — a public health concern cited by both EPA and FDA in their restrictions.

---

QDRO's Position

QDRO does not use triclosan in either v.daily or v.pro "Second Enamel" lines.

The issue is not purely regulatory. An antibacterial agent that works through a single enzyme target, accumulates in the body, and carries unresolved questions about hormonal disruption has no place in a product used twice daily for years. Cleaner alternatives exist.

In v.daily, antibacterial function is handled by cetylpyridinium chloride and zinc citrate — both well-characterised, non-accumulating, and free of endocrine concerns. In v.pro, the emphasis is on remineralisation via nano-hydroxyapatite: a well-mineralised enamel surface is physically less hospitable to acid-producing bacteria — a different and more durable kind of prevention.

---

Sources:

• Nabi N et al. (1989). The effect of a triclosan-containing dentifrice on established plaque and gingivitis. Clin Prev Dent. PMID: 8501272
• Gunsolley JC (2006). A meta-analysis of six-month studies of antiplaque and antigingivitis agents. J Am Dent Assoc. PMID: 16208383
• Teles RP, Teles FR (2009). Antimicrobial agents used in the control of periodontal biofilms. Braz Oral Res. PMID: 15560802
• Haraszthy VI et al. (2010). Effect of triclosan/copolymer-containing toothpaste on the association between plaque and gingival bleeding. J Clin Periodontol. PMID: 16965523
• Koeppe ES et al. (2022). Triclosan and Its Consequences on the Reproductive, Cardiovascular and Thyroid Levels. Int J Environ Res Public Health. PMID: 36232730
• Aho E et al. (2022). The Influence of Triclosan on the Thyroid Hormone System in Humans — A Systematic Review. Front Endocrinol. PMC9202756